The most pressing clinical challenge facing prostate cancer patients is that their disease evolves over time into a type called Neuroendocrine. This type of prostate cancer does not respond to drug therapies and spreads very quickly, making it highly lethal. Our group has identified that these cancers express a neurodevelopmental gene, Engrailed2, not in early tumours but only during the time that the cancer is evolving into the Neuroendocrine type. From our previous research we have found that Engrailed2 increases prostate cancer cells ability to migrate but has no effect on growth rate. The present project proposal extends this work, presently funded by RFD, to idenitify exactly how Engrailed2 is changing prostate cancer cells so that they migrate faster. By doing that we can then identify ways of turning this ability off. Thus our intent to find ways to stop prostate cancer from spreading to other parts of the body. Surgeons can effectively remove tumours if they remain in one place, but once it spreads, options become very limited and death commonly follows.